Immunome's (IMNM) Outperform Rating Reiterated at Wedbush

Immunome (NASDAQ:IMNM - Get Free Report)'s stock had its "outperform" rating restated by Wedbush in a report issued on Monday,RTT News reports. They presently have a $33.00 price target on the stock. Wedbush's price objective points to a potential upside of 276.28% from the stock's current price.

Separately, Piper Sandler decreased their price target on Immunome from $23.00 to $21.00 and set an "overweight" rating for the company in a research note on Thursday, November 14th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Immunome currently has an average rating of "Buy" and an average price target of $27.17.

Immunome Stock Performance

Immunome stock traded down $0.16 during midday trading on Monday, reaching $8.77. The stock had a trading volume of 453,030 shares, compared to its average volume of 896,133. The firm's fifty day simple moving average is $9.98 and its 200-day simple moving average is $11.80. Immunome has a 1-year low of $8.39 and a 1-year high of $26.70. The stock has a market capitalization of $699.64 million, a P/E ratio of -1.08 and a beta of 1.93.

Insider Transactions at Immunome

In other Immunome news, CEO Clay B. Siegall bought 150,000 shares of Immunome stock in a transaction dated Friday, January 31st. The stock was bought at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the purchase, the chief executive officer now owns 669,636 shares of the company's stock, valued at $5,189,679. The trade was a 28.87 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.60% of the stock is currently owned by corporate insiders.

Remove Ads

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets bought a new position in shares of Immunome during the 4th quarter worth approximately $70,000. KLP Kapitalforvaltning AS acquired a new stake in Immunome during the 4th quarter worth approximately $75,000. AlphaQuest LLC lifted its holdings in Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock worth $84,000 after purchasing an additional 7,867 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Immunome by 482.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after purchasing an additional 7,129 shares during the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in Immunome during the 4th quarter worth approximately $95,000. 44.58% of the stock is currently owned by institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.